s1pr1 Antibody

What is S1PR1 and why are antibodies against it important in research?

S1PR1 (sphingosine-1-phosphate receptor 1) is a G-protein coupled receptor that binds sphingosine-1-phosphate to induce intracellular signaling pathways related to cell growth, differentiation, migration, and trafficking . Also known as EDG1 (endothelial differentiation gene 1), CD363, CHEDG1, D1S3362, or ECGF1, this protein plays crucial roles in regulating endothelial cell behavior, maintaining vascular integrity, and promoting angiogenesis . The protein has a molecular weight of approximately 42.8 kilodaltons according to calculations, though observed molecular weights in experiments may differ (such as 68 kDa in some western blot applications) .

Antibodies against S1PR1 are essential research tools for detecting, localizing, and studying this receptor's expression and function across various tissues and experimental conditions. These antibodies enable visualization of receptor trafficking, quantification of expression levels, and investigation of protein-protein interactions that reveal fundamental biological mechanisms . The development of well-characterized antibodies has been crucial in advancing our understanding of S1PR1's role in immune cell regulation, vascular development, and various pathological conditions.

What applications can S1PR1 antibodies be used for in research?

S1PR1 antibodies can be employed across multiple experimental techniques, with each application providing distinct insights into protein expression, localization, and function:

Different antibodies demonstrate varying efficacy across these applications, making antibody selection critical to experimental success . For instance, according to search results, the Abcam anti-S1P1/EDG1 antibody has been validated for WB, FCM, ICC, IF, IHC-p, and IP applications with citations in 32 published studies, while other antibodies may have more limited application profiles .

How do I select the appropriate S1PR1 antibody for my specific research needs?

Selecting the optimal S1PR1 antibody requires careful consideration of several factors to ensure experimental validity and reproducibility:

Species Reactivity: First, determine which species you're studying (human, mouse, rat, etc.) and ensure the antibody has been validated for that species . Cross-reactivity between species should be confirmed experimentally rather than assumed, as sequence homology does not guarantee epitope conservation.

Antibody Type: Consider whether monoclonal or polyclonal antibodies better suit your research needs:

• Monoclonal antibodies (like the one described in result ) offer high specificity for a single epitope but may have lower sensitivity

• Polyclonal antibodies (like Boster's A01502) recognize multiple epitopes, potentially providing stronger signals but with increased risk of non-specific binding

Application Compatibility: Verify the antibody has been validated for your specific application through published citations or manufacturer validation data . Some antibodies perform well in certain applications but poorly in others due to epitope accessibility differences between native and denatured proteins.

Clone Selection: For monoclonal antibodies, different clones recognize different epitopes, which may affect performance in specific applications or under certain experimental conditions . Recent collaborative initiatives have characterized commercial antibodies to address reproducibility issues, providing valuable guidance for clone selection .

Validation Evidence: Prioritize antibodies with robust validation data, particularly those with knockout controls demonstrating specificity . Consider antibodies characterized in standardized protocols comparing readouts in knockout cell lines and isogenic parental controls, as described in result .

What are the optimal methods for validating S1PR1 antibodies before experimental use?

Proper antibody validation is essential for reliable research outcomes. For S1PR1 antibodies, implement these validation strategies:

Knockout Verification: The gold standard validation approach uses S1PR1 knockout cells or tissues as negative controls . This approach conclusively demonstrates antibody specificity by comparing signal between knockout and wild-type samples under identical conditions.

Overexpression Systems: Complementary to knockout validation, testing antibodies in cells overexpressing tagged versions of S1PR1 can confirm specific binding and determine sensitivity thresholds . The study described in result used this approach when developing a novel monoclonal S1PR1 antibody.

Multiple Detection Methods: Validate antibody performance across multiple techniques (e.g., western blot, immunofluorescence, flow cytometry) to ensure consistent target recognition regardless of protein conformation or experimental conditions .

Peptide Competition Assays: For antibodies raised against synthetic peptides (like Boster's A01502, which uses a 14-amino acid synthetic peptide near the carboxy terminus), conduct peptide blocking experiments to confirm epitope specificity . Pre-incubation with the immunizing peptide should abolish specific binding if the antibody is truly targeting S1PR1.

Isoform Specificity Testing: Verify whether the antibody distinguishes between S1PR1 isoforms, as noted in result : "At least two isoforms of S1P1 are known to exist; this S1P1 antibody will only recognize the shorter isoform." This information is critical when studying specific isoforms.

What are the key methodological considerations for immunofluorescence detection of S1PR1?

Immunofluorescence (IF) optimization for S1PR1 detection requires attention to several critical parameters:

Fixation Protocol: The method described in result used 4% paraformaldehyde fixation for 10 minutes at room temperature, which preserves epitope accessibility while maintaining cellular architecture . Alternative fixation methods (methanol, acetone, or glutaraldehyde) may offer advantages for specific experimental questions but require validation.

Permeabilization Optimization: For this transmembrane receptor, permeabilization conditions significantly impact epitope accessibility. The protocol in result used 0.2% Triton X-100 in PBS for 7 minutes . Titration of detergent concentration and exposure time is recommended to balance membrane permeabilization with preservation of receptor localization.

Blocking Conditions: Non-specific binding should be blocked with 5% fetal calf serum in PBS for 45 minutes as described in the characterized protocol . Alternative blocking agents (BSA, normal serum from the secondary antibody species, commercial blocking buffers) should be compared empirically.

Antibody Dilution: Primary antibody concentration requires careful optimization through titration. The protocol in result used a 1:75 dilution for their monoclonal antibody . Sub-optimal concentrations result in weak signals, while excessive antibody leads to high background.

Sequential Double-Labeling: When performing co-localization studies, sequential rather than simultaneous incubation with primary antibodies may prevent steric hindrance. Secondary antibodies should be highly cross-adsorbed to prevent cross-reactivity in multi-color experiments.

Counterstaining Strategy: Nuclear counterstaining with DAPI provides crucial contextual information for interpreting S1PR1 localization, as implemented in the protocol from result . Additional markers for subcellular compartments (endoplasmic reticulum, Golgi, plasma membrane) can further clarify receptor trafficking patterns.

How can researchers effectively troubleshoot inconsistent results with S1PR1 antibodies?

When confronting inconsistent results with S1PR1 antibodies, systematic troubleshooting approaches can identify and resolve experimental issues:

Antibody Degradation Assessment: S1PR1 antibodies should be stored according to manufacturer recommendations (typically 4°C for short-term and -20°C for long-term storage) . Repeated freeze-thaw cycles significantly reduce antibody performance. Aliquoting antibodies upon receipt prevents degradation from multiple freeze-thaw cycles.

Protocol Standardization: Inconsistencies often stem from subtle protocol variations. Developing detailed standard operating procedures (SOPs) that specify precise buffer compositions, incubation times/temperatures, and washing steps is essential for reproducibility across experiments and between laboratory members.

Batch Effects Monitoring: Document antibody lot numbers, as performance can vary between manufacturing batches. When possible, validate new lots against previous ones before implementing them in critical experiments. The collaborative initiative described in result addresses antibody reproducibility issues by characterizing commercial antibodies using standardized protocols .

Cell Line Authentication: S1PR1 expression levels vary significantly between cell types and culture conditions. Regular authentication of cell lines prevents misidentification issues, while passage number tracking helps identify expression changes in long-term cultures.

Sample Preparation Variables: For membrane proteins like S1PR1, sample preparation significantly impacts detection. Optimize lysis conditions for western blotting, fixation parameters for microscopy, and permeabilization methods for flow cytometry individually rather than assuming protocols are transferable between applications.

Signaling-Dependent Epitope Masking: Consider that S1PR1 conformation and complex formation may change upon ligand binding or downstream signaling activation. Time-course experiments following stimulation with sphingosine-1-phosphate can reveal dynamic changes in antibody accessibility to epitopes.

What approaches are recommended for studying S1PR1 trafficking using antibody-based techniques?

Investigating S1PR1 trafficking dynamics presents unique challenges that require specialized experimental approaches:

Live-Cell Imaging Optimization: For real-time trafficking studies, consider using antibody fragments (Fab) conjugated to fluorophores, which minimize potential interference with receptor function while allowing dynamic visualization. Alternatively, correlate antibody-based fixed-cell imaging with live-cell studies using fluorescently-tagged S1PR1 constructs.

Pulse-Chase Antibody Labeling: To track receptor internalization kinetics, implement pulse-chase protocols where surface S1PR1 is labeled with primary antibody at 4°C (preventing internalization), followed by warming to 37°C to permit trafficking. Sequential labeling with different secondary antibodies at various timepoints can distinguish surface from internalized receptor populations.

Endosomal Compartment Co-localization: Combine S1PR1 antibody labeling with markers for distinct endosomal compartments (early endosomes: EEA1; recycling endosomes: Rab11; late endosomes: Rab7; lysosomes: LAMP1) to map trafficking routes following receptor activation. This approach reveals degradation versus recycling fates of the receptor.

Trafficking Perturbation Tools: Employ pharmacological inhibitors or genetic approaches targeting trafficking machinery components to dissect mechanism:

• Dynamin inhibitors (Dynasore) block endocytosis

• Brefeldin A disrupts Golgi-mediated transport

• Bafilomycin A1 prevents endosomal acidification

• siRNA knockdown of Rab GTPases or adaptor proteins

Surface Biotinylation Assays: Complement imaging with biochemical approaches where cell-surface proteins are biotinylated, followed by internalization periods, stripping of remaining surface biotin, and precipitation of biotinylated (internalized) proteins. Subsequent western blotting with S1PR1 antibodies quantifies internalization rates.

How do different fixation and permeabilization methods affect S1PR1 antibody performance?

The choice of fixation and permeabilization procedures significantly impacts S1PR1 antibody performance due to its seven-transmembrane domain structure:

Fixation Method Comparison:

Permeabilization Considerations:

Detergent selection and concentration require careful optimization:

• Triton X-100 (0.1-0.5%): Effective for general permeabilization but may extract membrane proteins (0.2% for 7 minutes was used in result )

• Saponin (0.01-0.1%): Milder detergent that preserves membrane structure

• Digitonin (0.001-0.01%): Selective permeabilization of plasma membrane while leaving nuclear membranes intact

• No permeabilization: For exclusive detection of extracellular epitopes

Sequential Versus Simultaneous Processing:

Consider the timing of fixation relative to antibody labeling:

• Pre-fixation labeling: Preserves native epitopes but limited to surface detection

• Post-fixation labeling: Allows intracellular detection but may reduce epitope accessibility

• Live-cell labeling followed by fixation: Captures dynamic processes before preservation

Each approach offers distinct advantages depending on whether the experimental question focuses on total S1PR1 expression, surface-to-internal distribution, or trafficking dynamics.

What strategies can effectively distinguish between S1PR1 isoforms using antibodies?

Discriminating between S1PR1 isoforms requires careful antibody selection and complementary experimental approaches:

Isoform-Specific Antibody Selection: As noted in result , some antibodies recognize only specific isoforms: "At least two isoforms of S1P1 are known to exist; this S1P1 antibody will only recognize the shorter isoform." When studying multiple isoforms, select antibodies with defined epitopes relative to isoform-specific regions.

Molecular Weight Discrimination: Supplement antibody specificity with molecular weight analysis in western blotting. The calculated molecular weight of S1PR1 is 42.8 kDa, while the observed molecular weight can be 68 kDa in some experimental systems, potentially reflecting post-translational modifications or isoform differences .

Recombinant Isoform Controls: Generate expression constructs for each specific isoform to serve as positive controls for antibody validation. These controls should ideally incorporate epitope tags (FLAG, HA, V5) distinct from the antibody epitope to permit orthogonal detection.

Isoform-Selective Knockdown: Implement siRNA or shRNA approaches targeting isoform-specific sequences to create selective knockdown controls. Antibodies claiming isoform specificity should show differential signal reduction corresponding to the targeted isoform.

Mass Spectrometry Validation: For definitive isoform identification, combine immunoprecipitation using anti-S1PR1 antibodies with mass spectrometry analysis of the precipitated proteins. This approach identifies specific peptides unique to each isoform, confirming antibody selectivity.

What are the most robust approaches for quantifying S1PR1 expression levels in different tissue samples?

Accurate quantification of S1PR1 expression requires consideration of methodological limitations and implementation of appropriate controls:

Western Blot Quantification: For semi-quantitative analysis, implement these critical controls:

• Loading controls (β-actin, GAPDH) must be selected based on expression stability across experimental conditions

• Standard curves using recombinant S1PR1 protein establish the linear detection range

• Biological replicates (n ≥ 3) enable statistical analysis

• Multiple antibodies targeting different epitopes confirm specificity

Flow Cytometry Optimization: For single-cell quantification:

• Fluorescence minus one (FMO) controls establish positive population boundaries

• Standardized beads calibrate fluorescence intensity to molecules of equivalent soluble fluorochrome (MESF)

• Compensation matrices correct for spectral overlap in multiparameter analysis

• Dead cell exclusion prevents false-positive signals from autofluorescence

Immunohistochemistry Scoring: For tissue expression patterns:

• Implement automated image analysis with machine learning algorithms for unbiased quantification

• Use H-score or Allred scoring systems combining intensity and percentage positive cells

• Include positive and negative control tissues in each staining batch

• Employ at least two independent pathologists for scoring validation

Quantitative PCR Correlation: Complement protein detection with mRNA quantification:

• Design primers spanning exon-exon junctions to prevent genomic DNA amplification

• Validate primer efficiency using standard curves

• Select reference genes empirically verified for stability in the tissue of interest

• Consider potential dissociation between mRNA and protein levels due to post-transcriptional regulation

How can researchers effectively study S1PR1-protein interactions using antibody-based approaches?

Investigating S1PR1 interactions with other proteins requires specialized techniques that preserve complex integrity:

Co-Immunoprecipitation Optimization: When immunoprecipitating S1PR1:

• Use mild lysis conditions (1% digitonin or 0.5% CHAPS rather than stronger detergents) to preserve membrane protein complexes

• Include protease and phosphatase inhibitors to prevent complex degradation during processing

• Conduct reciprocal IPs (immunoprecipitate with anti-S1PR1 then blot for partner, and vice versa)

• Pre-clear lysates with species-matched non-immune IgG to reduce non-specific binding

• Include negative controls (IgG-only IP, S1PR1-null cells) for specificity verification

Proximity Ligation Assay (PLA): This technique visualizes protein-protein interactions with nanometer resolution:

• Requires two primary antibodies from different species targeting the interaction partners

• Species-specific secondary antibodies conjugated to complementary oligonucleotides enable rolling-circle amplification when proteins are in close proximity (<40 nm)

• Results in distinct fluorescent puncta representing individual interaction events

• Provides spatial information about interaction sites within cells

FRET-Based Approaches: Förster resonance energy transfer detects molecular proximity:

• Implement antibody-based FRET using directly labeled primary antibodies or fluorophore-conjugated secondary antibodies

• Calculate FRET efficiency through acceptor photobleaching or sensitized emission measurements

• Control for spectral bleed-through and cross-talk with appropriate single-label controls

• Consider antibody size (~10 nm) when interpreting FRET distances

Cross-Linking Mass Spectrometry: For unbiased interaction mapping:

• Apply membrane-permeable cross-linkers to stabilize transient interactions

• Immunoprecipitate S1PR1 complexes under denaturing conditions

• Identify cross-linked peptides through specialized mass spectrometry workflows

• Map interaction interfaces at amino acid resolution

What novel antibody-based approaches are advancing S1PR1 research?

Recent technological developments have expanded the toolkit for studying S1PR1 biology:

Single-Domain Antibodies (Nanobodies): These camelid-derived single-chain antibody fragments offer advantages for studying membrane proteins like S1PR1:

• Smaller size (~15 kDa vs. ~150 kDa for conventional antibodies) allows access to sterically hindered epitopes

• Superior penetration into tissues and dense cellular structures

• Expression as intrabodies for real-time tracking of native S1PR1 in living cells

• Potential for improved crystallization of membrane protein complexes

Antibody Engineering for Super-Resolution Microscopy: Modified antibodies enhance resolution beyond the diffraction limit:

• Site-specific conjugation with photoactivatable fluorophores for PALM/STORM imaging

• Minimized linkage error through directly conjugated Fab fragments

• Multi-epitope labeling strategies for quantitative point counting

• Correlative light-electron microscopy approaches using gold-conjugated antibodies

Spatially-Resolved Antibody Techniques: Methods revealing S1PR1 distribution at tissue level:

• Imaging mass cytometry combines antibody specificity with mass spectrometry resolution

• Multiplexed ion beam imaging (MIBI) enables simultaneous detection of dozens of targets

• Spatial transcriptomics correlated with antibody staining links protein expression to local transcriptomes

• Highly multiplexed immunofluorescence through iterative staining and bleaching protocols

Antibody-Drug Conjugates as Research Tools: Beyond therapeutic applications:

• Targeted degradation of S1PR1 using antibody-PROTAC conjugates

• Selective modulation of signaling using antibody-delivered kinase inhibitors

• Temporal control through photocleavable antibody conjugates

• Cell-specific knockout via antibody-guided CRISPR delivery

How can contradictory results with different S1PR1 antibodies be resolved and interpreted?

Conflicting results when using different S1PR1 antibodies require systematic investigation:

Epitope Mapping Analysis: Determine precisely where each antibody binds:

• Epitope competition assays reveal whether antibodies recognize the same or different regions

• Peptide arrays or alanine scanning mutagenesis identify critical binding residues

• Computational prediction of epitope accessibility in different protein conformations

• Cross-reference epitopes with known post-translational modification sites that might affect antibody binding

Validation in Defined Genetic Models: Leverage genetic approaches for definitive validation:

• Test all antibodies in parallel on samples from S1PR1 knockout models as described in result

• Create epitope-tagged knock-in models expressing native levels of S1PR1

• Implement inducible expression systems to create defined expression gradients

• Use CRISPR/Cas9 to introduce epitope-disrupting mutations

Integrated Multi-Antibody Approach: Develop consensus from multiple reagents:

Biological Context Consideration: Evaluate whether discrepancies reflect biological phenomena:

• S1PR1 conformation changes upon ligand binding may alter epitope accessibility

• Protein interactions might mask specific epitopes in a context-dependent manner

• Post-translational modifications (phosphorylation, ubiquitination, glycosylation) may affect antibody binding

• Splice variants or proteolytic processing could explain differential detection

The collaborative initiative described in result represents an important approach to addressing antibody reproducibility issues by characterizing commercially available antibodies through standardized protocols .

What are the most critical considerations for ensuring reproducible S1PR1 antibody-based research?

Ensuring reproducibility in S1PR1 antibody research requires attention to several fundamental principles:

Comprehensive Antibody Reporting: Documentation should include:

• Complete antibody identification (manufacturer, catalog number, lot number, RRID)

• Detailed validation evidence specific to the experimental system and application

• Explicit description of dilution factors, incubation times, and buffer compositions

• Clear articulation of positive and negative controls employed

• Raw data availability for key validation experiments

Standardized Protocols: Implement consistent methodologies as exemplified in result :

• Develop and share detailed protocols that can be precisely replicated

• Benchmark protocols against those used in published validation studies

• Participate in collaborative validation initiatives

• Maintain consistent protocols across longitudinal studies

• Document any protocol modifications with appropriate revalidation

Biological Variables Control: Account for factors affecting S1PR1 expression:

• Cell culture conditions (passage number, confluence, serum factors)

• Circadian rhythm effects on receptor expression

• Physiological state of research animals or human subjects

• Tissue-specific expression patterns and potential interfering substances

• Activation state of signaling pathways that might regulate receptor levels

Technical Replication Strategy: Design experiments with appropriate replication:

• Independent biological replicates (different animals/cell preparations)

• Technical replicates to assess methodological variation

• Blinded analysis to prevent unconscious bias

• Power analysis to determine required sample sizes

• Pre-registration of experimental designs when possible